Hormone replacement therapy and risk of venous thromboembolism: population based case-control study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the association between use of hormone replacement therapy and the risk of idiopathic venous thromboembolism. Design: Population based case-control study. Setting: Population enrolled in the General Practice Research Database, United Kingdom. Subjects: A cohort of 347 253 women aged 50 to 79 without major risk factors for venous thromboembolism was identified. Cases were 292 women admitted to hospital for a first episode of pulmonary embolism or deep venous thrombosis; 10 000 controls were randomly selected from the source cohort. Main outcome measures: Adjusted relative risks estimated from unconditional logistic regression. Results: The adjusted odds ratio of venous thromboembolism for current use of hormone replacement therapy compared with non-users was 2.1 (95% confidence interval 1.4 to 3.2). This increased risk was restricted to first year users, with odds ratios of 4.6 (2.5 to 8.4) during the first six months and 3.0 (1.4 to 6.5) 6-12 months after starting treatment. No major risk differences were observed between users of low and high doses of oestrogens, unopposed and opposed treatment, and oral and transdermal preparations. The risk of idiopathic venous thromboembolism among non-users of replacement therapy was estimated to be 1.3 per 10 000 women per year. Among current users, idiopathic venous thromboembolism occurs at two to three times the rate in non-users, resulting in one to two additional cases per 10 000 women per year. Conclusions: Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Risk of venous thromboembolism in users of hormone replacement therapy
Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gough, P., & Marsh, S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07113-9 · Cited by 819
Jick, H., Derby, L. E., Myers, M. W., Vasilakis, C., & Newton, K. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07114-0 · Cited by 602
Prospective study of exogenous hormones and risk of pulmonary embolism in women
Grodstein, F., Stampfer, M. J., Goldhaber, S. Z., Manson, J. E., Colditz, G. A., Speizer, F. E., Willett, W. C., & Hennekens, C. H. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07308-4 · Cited by 571
Prior to Use of Estrogen Replacement Therapy, Are Users Healthier than Nonusers?
Matthews, K. A., Kuller, L. H., Wing, R. R., Meilahn, E. N., & Plantinga, P. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008678 · Cited by 517
NACHTIGALL, L. E., NACHTIGALL, R. H., NACHTIGALL, R. D., & BECKMAN, M. E. (1979) · Obstetrics & Gynecology · doi:10.1097/00006250-197907000-00017 · Cited by 446
Effects of long-term estrogen replacement therapy
Hammond, C. B., Jelovsek, F. R., Lee, K. L., Creasman, W. T., & Parker, R. T. (1979) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(79)90288-6 · Cited by 370
the Boston Collaborative Drug Surveillance Program, B. U. M. C. (1974) · New England Journal of Medicine · doi:10.1056/nejm197401032900104 · Cited by 345
Jick, H., Terris, B. Z., Derby, L. E., & Jick, S. S. (1992) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2630010607 · Cited by 265
EVIDENCE OF A HEALTHY ESTROGEN USER SURVIVOR EFFECT
Sturgeon, S. R., Schairer, C., Brinton, L. A., Pearson, T., & Hoover, R. N. (1995) · Epidemiology · doi:10.1097/00001648-199505000-00006 · Cited by 188
Cited by
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based Case-Control Study
Heit, J. A., Silverstein, M. D., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.809 · Cited by 2,171
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930
Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002) · JAMA · doi:10.1001/jama.288.7.872 · Cited by 990
Estrogen Therapy in Postmenopausal Women: Effects on Cognitive Function and Dementia
Yaffe, K., Sawaya, G., Lieberburg, I., & Grady, D. (1998) · JAMA · doi:10.1001/jama.279.9.688 · Cited by 941
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 864
Pharmacology of estrogens and progestogens: influence of different routes of administration
Kuhl, H. (2005) · Climacteric · doi:10.1080/13697130500148875 · Cited by 835
Grady, D., Wenger, N. K., Herrington, D., Khan, S., Furberg, C., Hunninghake, D., Vittinghoff, E., Hulley, S., & for the Heart and Estrogen/progestin Replacement Study Research Group (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00002 · Cited by 715
Scarabin, P.-Y., Oger, E., & Plu-Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 714
Estrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
HORMONE REPLACEMENT THERAPY, HEART DISEASE, AND OTHER CONSIDERATIONS
Barrett-Connor, E., & Grady, D. (1998) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.19.1.55 · Cited by 590
Validity of the General Practice Research Database
Jick, S. S., Kaye, J. A., Vasilakis‐Scaramozza, C., Rodríguez, L. A. G., Ruigómez, A., Meier, C. R., Schlienger, R. G., Black, C., & Jick, H. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.686.32205 · Cited by 584
The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
Rathbun, S. (2009) · Circulation · doi:10.1161/circulationaha.108.841403 · Cited by 575
The Epidemiology of Venous Thromboembolism in the Community
Mohr, D., Petterson, T., Lohse, C., O’Fallon, W. M., Melton, L. J., Heit, J., & Silverstein, M. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616243 · Cited by 571
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569
Use of the UK General Practice Research Database for pharmacoepidemiology
García Rodríguez, L. A., & Pérez Gutthann, S. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00701.x · Cited by 558
Hart, R. G., Pearce, L. A., McBride, R., Rothbart, R. M., & Asinger, R. W. (1999) · Stroke · doi:10.1161/01.str.30.6.1223 · Cited by 533
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
Renoux, C., Dell'Aniello, S., Garbe, E., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.c2519 · Cited by 386
Hulley, S., Furberg, C., & Barrett-Connor, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00920-0 · Cited by 339
Zondervan, K. T., Yudkin, P. L., Vessey, M. P., Dawes, M. G., Barlow, D. H., & Kennedy, S. H. (1999) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08140.x · Cited by 324
Investigation and management of heritable thrombophilia
Walker, I. D., Greaves, M., & Preston, F. E. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02981.x · Cited by 299
Canonico, M., Fournier, A., Carcaillon, L., Olié, V., Plu-Bureau, G., Oger, E., Mesrine, S., Boutron-Ruault, M.-C., Clavel-Chapelon, F., & Scarabin, P.-Y. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.196022 · Cited by 272
Vehkavaara, S., Silveira, A., Hakala-Ala-Pietilä, T., Virkamäki, A., Hovatta, O., Hamsten, A., Taskinen, M.-R., & Yki-Järvinen, H. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615643 · Cited by 270
Female Hormones and Thrombosis
Rosendaal, F. R., Helmerhorst, F. M., & Vandenbroucke, J. P. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0202.102318 · Cited by 267
Clarke, S. (2002) · BJOG: An International Journal of Obstetrics and Gynaecology · doi:10.1016/s1470-0328(02)01544-6 · Cited by 267
Venous Thrombosis: The Role of Genes, Environment, and Behavior
Rosendaal, F. R. (2005) · Hematology · doi:10.1182/asheducation-2005.1.1 · Cited by 253
O'Sullivan, A. J., Crampton, L. J., Freund, J., & Ho, K. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2773 · Cited by 210
“The oral dose of estrogen used for menopausal replacement therapy is generally lower than that used in the present study with a recent study reporting that 80% of estrogen users are taking a lower dose (36).”
MethodEffects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review
Goldštajn, M. Š., Mikuš, M., Ferrari, F. A., Bosco, M., Uccella, S., Noventa, M., Török, P., Terzic, S., Laganà, A. S., & Garzon, S. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06647-5 · Cited by 111
Renoux, C., Dell'Aniello, S., Brenner, B., & Suissa, S. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4197 · Cited by 80
Effects of high dose oestrogen therapy on circulating inflammatory markers
Wilson, R., Spiers, A., Ewan, J., Johnson, P., Jenkins, C., & Carr, S. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.01.009 · Cited by 59
“Differential effects of oral and transdermal oestrogen replacement therapy have been found, with oral oestrogen being associated with a significant rise in the levels of inflammatory markers, whilst transdermal oestrogen was associated with no such change [8,10,11].”
BackgroundLowe, G. D. O. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01400.x · Cited by 54
Gomes, M. P. V., & Deitcher, S. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.1965 · Cited by 44
Metadata
- Authors
- Gutthann, S. P., Rodriguez, L. A. G., Castellsague, J., & Oliart, A. D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1997-03-15
- Volume
- 314
- Issue
- 7083
- Pages
- 796
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2021062942
- Cited by
- 338
- References
- 16
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.